GeneBio Systems

PDL1 ELISA kit (Human)

Name: PDL1 ELISA kit (Human)
Brand: GeneBio Systems
SKU: SEA788Hu
Price: 165700 JPY
Availability: InStock

SKU:SEA788Hu

¥165,700 JPY

Sale Sold out

Shipping calculated at checkout.

Quantity

Size: 96Tests

# of Times Cited in literature: 45

Prepare Time: 1-3 days(please inquire for mutiple units)

Target Name: PDL1

Target Full Name: Programmed Cell Death Protein 1 Ligand 1

Alternative Names: CD274; PDCD1LG1; B7-H; B7H1; PD-L1; PDCD1L1; PDCD1-LG1; Programed Death Ligand 1

Target Species: Human

Uniprot: Q9NZQ7

Gene ID: 29126

Featured Series: SE kit

Featured Series Function: Detects protein (regular version)

Specificity: Reactive with Human PDL1 / Programmed Cell Death Protein 1 Ligand 1

Method: Colormetric

Detection principle: Double-antibody Sandwich

Detection range: 0.156-10ng/mL

Sensitivity: 0.056ng/mL

Assay Time: 3h

Sample Size: 100uL

Recommended/Predicted Sample Types: Serum, Plasma, Tissue Homogenates and other Biological Fluids

Assay Precision: Intra-Assay: CV<10%, Inter-Assay: CV<12%

Reproducibility test menthod: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Programmed Cell Death Protein 1 Ligand 1 (PDL1) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Programmed Cell Death Protein 1 Ligand 1 (PDL1) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100

Storage: 4°C for 1 month/ -20°C for long-term(One year within shelf life)

Shelf-life: 12 months

Specificity: This assay has high sensitivity and excellent specificity for detection of Programmed Cell Death Protein 1 Ligand 1 (PDL1). No significant cross-reactivity or interference between Programmed Cell Death Protein 1 Ligand 1 (PDL1) and analogues was observed.

Stability: The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Assay procedure summary: 1. Prepare all reagents, samples and standards; 2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C; 3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C; 4. Aspirate and wash 3 times; 5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C; 6. Aspirate and wash 5 times; 7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C; 8. Add 50µL Stop Solution. Read at 450nm immediately.

Test principle: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Programmed Cell Death Protein 1 Ligand 1 (PDL1). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Programmed Cell Death Protein 1 Ligand 1 (PDL1). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Programmed Cell Death Protein 1 Ligand 1 (PDL1), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Programmed Cell Death Protein 1 Ligand 1 (PDL1) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Research Area: Signal transduction;Tumor immunity;Infection immunity;Immune molecule;Autoimmunity;

References Citing This Product: Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications

High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial.

PD‐L1 gene polymorphisms and low serum level of PD‐L1 protein are associated to type 1 diabetes in Chile

Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study

High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.

Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer

PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma

High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.

Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predictssurvival in advanced biliary tract cancer patients treated with palliative chemotherapy.

High post-treatment serum levels of soluble programmed cell death ligand 1 predict earlyrelapse and poor prognosis in extranodal NK/T cell lymphoma patients.

Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma